News

Ranbaxy and Nippon Chemiphar (NC) have announced the dissolution of their joint venture ‘Nihon Pharmaceutical Industry Co Ltd’ (NPI), in Japan. This follows an agreement between the two

Alexion has presented new data, which demonstrates the severe clinical burden of paroxysmal nocturnal hemoglobinuria (PNH) and the clinical benefits of Soliris (eculizumab) in 44 patients with no

Trubion Pharmaceuticals and Facet Biotech have presented the positive data from a phase 1 study of TRU-016 in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) at

Novo Nordisk and ZymoGenetics has announced an agreement where Novo Nordisk in-licenses a fully-human anti-IL21 monoclonal antibody (IL-21 mAb) developed by ZymoGenetics, and broad intellectual property rights covering

Actelion has decided to proceed with advanced clinical development with its orally available and selective S1P1 receptor agonist (ACT-128800) in psoriasis. ACT-128800 is already in advanced clinical development

Neovacs has initiated Phase IIa clinical study of its TNFa Kinoid immunotherapy in rheumatoid arthritis patients who have ceased to respond to an anti-TNFa monoclonal antibody and who

Galapagos has initiated clinical Phase I development of the first small molecule candidate from its arthritis alliance with GlaxoSmithKline (GSK). For entering the clinic with candidate drug GLPG0555,

Rib-X Pharmaceuticals (Rib-X) has entered into a further license agreement with Yale University in the area of ribosome and antibiotic structure and function. Under the agreement, Rib-X is

ImmunoGen has presented positive initial clinical findings with SAR3419 at the American Society of Hematology (ASH) 51st Annual Meeting and Exposition. Among the findings reported were responses to